Treatment of newly diagnosed myeloma in patients not eligible for transplantation

Current Hematologic Malignancy Reports

Volumn 6, Issue 2, 2011, Pages 113-119

  Mateos, M Victoria ^a   San Miguel, Jesús ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Bortezomib; Elderly patients; IMiDs, Toxicity; Lenalidomide; Multiple myeloma; Not eligible for transplantation; Thalidomide; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE;

ARTICLE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LOW DRUG DOSE; MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; SOMNOLENCE; THROMBOCYTOPENIA; WEAKNESS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79957527693     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0080-3     Document Type: Article

References (30)

1. SK Kumar SV Rajkumar A Dispenzieri MQ Lacy SR Hayman FK Buadi, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood. 111 5 2516 20 17975015 10.1182/blood-2007-10-116129 1:CAS:528: DC%2BD1cXivFaktrk%3D
2. H Brenner A Gondos D Pulte 2008 Recent major improvement in long-term survival of younger patients with multiple myeloma Blood. 111 5 2521 6 17901246 10.1182/blood-2007-08-104984 1:CAS:528:DC%2BD1cXivFaktrY%3D
3. A Palumbo S Bringhen T Caravita E Merla V Capparella V Callea, et al. 2006 Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet. 367 9513 825 31 16530576 10.1016/S0140-6736(06)68338-4 1:CAS:528:DC%2BD28Xit1eht7c%3D (Pubitemid 43363369)
4. T Facon JY Mary C Hulin L Benboubker M Attal B Pegourie, et al. 2007 Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet. 370 9594 1209 18 17920916 10.1016/S0140-6736(07)61537-2 1:CAS:528:DC%2BD2sXhtFehsr%2FN (Pubitemid 47516593)
5. C Hulin T Facon P Rodon B Pegourie L Benboubker C Doyen, et al. 2009 Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial J Clin Oncol. 27 22 3664 70 19451428 10.1200/JCO.2008.21.0948 1:CAS:528:DC%2BD1MXhtVOnu7bJ
6. A Waage P Gimsing P Fayers N Abildgaard L Ahlberg B Bjorkstrand, et al. 2010 Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma Blood. 116 9 1405 12 20448107 10.1182/blood-2009-08-237974 1:CAS:528:DC%2BC3cXhtF2qsb%2FM
7. P Wijermans M Schaafsma F Termorshuizen R Ammerlaan S Wittebol H Sinnige, et al. 2010 Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study J Clin Oncol. 28 19 3160 6 20516439 10.1200/JCO.2009.26.1610 1:CAS:528:DC%2BC3cXpslajtL8%3D
8. M Beksac R Haznedar T Firatli-Tuglular H Ozdogu I Aydogdu N Konuk, et al. 2011 Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group Eur J Haematol. 86 1 16 22 20942865 10.1111/j.1600-0609.2010.01524.x 1:CAS:528:DC%2BC3MXhtlOls7c%3D
9. H Ludwig R Hajek E Tothova J Drach Z Adam B Labar, et al. 2009 Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma Blood. 113 15 3435 42 18955563 10.1182/blood-2008-07-169565 1:CAS:528:DC%2BD1MXkslCkurg%3D
10. GJ Morgan FE Davies WM Gregory SE Bell AJ Szubert K Cocks, et al. 2009 The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS [abstract] Blood (ASH Annual Meeting Abstracts) 114 22 352a
11. MV Mateos JM Hernandez MT Hernandez NC Gutierrez L Palomera M Fuertes, et al. 2006 Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Blood. 108 7 2165 72 16772605 10.1182/blood-2006-04-019778 1:CAS:528:DC%2BD28XhtVCgtbfI (Pubitemid 44497496)
12. JF San Miguel R Schlag NK Khuageva MA Dimopoulos O Shpilberg M Kropff, et al. 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 906 917 18753647 10.1056/NEJMoa0801479 1:CAS:528:DC%2BD1cXhtVGms77K The Vista trial demonstrated that bortezomib and melphalan plus prednisone is superior to melphalan plus prednisone alone in response rate, time to progression, progression free survival, and overall survival
13. MV Mateos PG Richardson R Schlag NK Khuageva MA Dimopoulos O Shpilberg, et al. 2010 Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial J Clin Oncol 28 13 2259 2266 20368561 10.1200/JCO.2009.26.0638 1:CAS:528:DC%2BC3cXpsFSgt7s%3D After a median follow-up of more than 3 years, bortezomib and melphalan plus prednisone continues to be superior to melphalan and prednisone alone in terms of overall survival
14. R Niesvizky IW Flinn RM Rifkin NY Gabrail V Charu B Clowney, et al. 2010 Patient-reported quality of life in elderly, newly diagnosed multiple myeloma patients treated with bortezomib-based regimens: results from the phase 3b UPFRONT study Blood (ASH Annual Meeting Abstracts) 116 21 3026a
15. SV Rajkumar S Jacobus NS Callander R Fonseca DH Vesole ME Williams, et al. 2010 Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol. 11 1 29 37 19853510 10.1016/S1470-2045(09)70284-0 1:CAS:528:DC%2BC3cXjslKrsg%3D%3D
16. DH Vesole S Jacobus SV Rajkumar R Abonour NS Callander PR Greipp, et al. 2010 Lenalidomide plus low-dose dexamethasone (Ld): superior one and two year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (LD) Blood (ASH Annual Meeting Abstracts) 116 21 308a
17. A Palumbo P Falco P Corradini A Falcone RF Di N Giuliani, et al. 2007 Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network J Clin Oncol. 25 28 4459 65 17785703 10.1200/JCO.2007.12.3463 1:CAS:528:DC%2BD2sXht1ertrjK (Pubitemid 350063804)
18. A Palumbo M Delforge J Catalano R Hajek M Kropff MT Petrucci, et al. 2010 A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients > = 65 years with newly diagnosed multiple myeloma (NDMM): Continuous use of lenalidomide vs fixed-duration regimens Blood (ASH Annual Meeting Abstracts) 116 21 622a
19. MV Mateos A Oriol J Martinez-Lopez N Gutierrez AI Teruel R de Paz, et al. 2010 Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Lancet Oncol. 11 10 934 41 20739218 10.1016/S1470-2045(10)70187-X 1:CAS:528:DC%2BC3cXht1ertLvE
20. A Palumbo S Bringhen D Rossi M Cavalli A Larocca R Ria, et al. 2010 Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial J Clin Oncol. 28 34 5101 9 20940200 10.1200/JCO.2010.29.8216 1:CAS:528:DC%2BC3MXltlKnsw%3D%3D
21. S Kumar IW Flinn PG Richardson P Hari NS Callander SJ Noga, et al. 2010 Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: Results from the multi-center, randomized, phase 2 EVOLUTION study Blood (ASH Annual Meeting Abstracts) 116 21 621a
22. S Singhal J Mehta R Desikan D Ayers P Roberson P Eddlemon, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med. 341 21 1565 71 10564685 10.1056/NEJM199911183412102 1:CAS:528:DyaK1MXotVSgs78%3D
23. GJ Morgan FE Davies WM Gregory SE Bell AJ Szubert N Navarro-Coy, et al. 2010 Thalidomide maintenance significantly improves progression-free survival (PFS) and overall survival (OS) of myeloma patients when effective relapse treatments are used: MRC Myeloma IX results Blood (ASH Annual Meeting Abstracts) 116 21 623a
24. P Kapoor S Kumar R Fonseca MQ Lacy TE Witzig SR Hayman, et al. 2009 Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone Blood. 114 3 518 21 19324902 10.1182/blood-2009-01-202010 1:CAS:528:DC%2BD1MXpt1Wmsb4%3D
25. A Palumbo S Bringhen M Cavalli R Ria M Offidani F Patriarca, et al. 2010 Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: updated follow-up and impact of prognostic factors ASH Annual Meeting Abstracts 116 21 620a
26. M-V Mateos NC Gutierrez B Paiva A Oriol J Martinez-Lopez AI Teruel, et al. 2010 Clinical outcome according to both cytogenetic abnormalities (CA) detected by fluorescence in situ hibridization (FISH) and hyperdiploidy assessed by flow cytometry (FCM) in elderly newly diagnosed myeloma patients treated with a bortezomib-based combination Blood (ASH Annual Meeting Abstracts) 116 21 309a
27. A Palumbo S Bringhen AM Liberati T Caravita A Falcone V Callea, et al. 2008 Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Blood. 112 8 3107 14 18505783 10.1182/blood-2008-04-149427 1:CAS:528:DC%2BD1cXht1Omur7P
28. M Offidani L Corvatta MN Piersantelli G Visani F Alesiani M Brunori, et al. 2006 Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma Blood. 108 7 2159 64 16763209 10.1182/blood-2006-03-013086 1:CAS:528:DC%2BD28XhtVCgtbfP (Pubitemid 44497495)
29. MV Mateos JM Hernández MT Hernández NC Gutiérrez L Palomera M Fuertes, et al. 2008 Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression Haematologica. 93 4 560 5 18322252 10.3324/haematol.12106 1:CAS:528:DC%2BD1cXhsVSiu7rM (Pubitemid 351536384)
30. Niesvizky R, Flinn IW, Rifkin RM, et al. Phase 3b UPFRONT Study: Safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116:Abstract 619.